Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has announced that its controlled partnership enterprise, GP Fund II, has entered into a Share Transfer Agreement to acquire an 11.04% equity interest in a target company from AHAPL, an independent third party. The acquisition, valued at RMB 748,807,492.58, aims to enhance strategic cooperation between the involved entities and is classified as a disclosable transaction under Hong Kong Listing Rules, exempt from shareholder approval.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
YTD Price Performance: 3.65%
Average Trading Volume: 1,769,764
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.86B
Learn more about 0874 stock on TipRanks’ Stock Analysis page.